The Tohoku journal of experimental medicine · 2024
Clinical Characteristics of the Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS).
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamaguchi Mizuki, Takakura Sho, Tanaka Hiroaki, Tamaishi Yuya, Magawa Shoichi, Maki Shintaro, Nii Masafumi, Tanaka Kayo, Toriyabe Kuniaki, Yamaguchi Kyohei, Makino Marie, Watashige Naoki, Maegawa Goki, Kondo Eiji, Ikeda Tomoaki
Аннотация
Adequate cervical ripening is essential before labor induction. However, effective methods for cervical ripening are limited in Japan. Although the controlled-release dinoprostone vaginal delivery system (PROPESS) was approved in Japan in 2020, it has not gained widespread acceptance over traditional methods. This observational study aimed to analyze the characteristics and precautions of the PROPESS based on cases of administration for cervical ripening conducted at five hospitals in the Mie Prefecture, Japan, between April 2020 and September 2021. We retrospectively evaluated cases wherein PROPESS was used for cervical ripening to determine its clinical characteristics. A total of 123 pregnant women were included in this study. The most common reason for PROPESS device removal was painful regular uterine contractions within 3 min after administration. Among these women, 48.5% had PROPESS removed within 4 h after administration. PROPESS removal due to non-reassuring fetal status occurred in 12 of the 123 (9.8%) women, with removal occurring within 4 h after administration in 8 of these cases. Among these eight cases, four (50.0%) had accompanying uterine hyperstimulation. The peak time from PROPESS administration to vaginal delivery was 28-32 h for primiparas and 4-8 h for multiparas. This study provides a comprehensive overview of PROPESS usage, highlighting the need for strict monitoring within 4 h after PROPESS administration to ensure its safety. This study provides valuable insights for facilities in Japan planning to implement the PROPESS in the future.